| Product | Clone/Type | Applications | Reactivity | Observed MW* | Key Features |
|---|---|---|---|---|---|
| ab128936 | EPR6454 (Rabbit mAb) | WB, IHC, IF, Flow Cytometry | Human, Mouse, Rat | 32 kDa (predicted), 35–100 kDa (observed) | Validated in multiple cell lines (Ramos, HeLa) |
| DF4807 | Rabbit pAb | WB, IF/ICC | Human, Rat | 32 kDa | Cross-reactivity predicted for pig, dog |
| ARG66252 | SQab1741 (Rabbit mAb) | Flow Cytometry, IHC-P | Human | N/A | Optimized for formalin-fixed tissues |
| #12922 | D4Y7H (Rabbit mAb) | WB, IP, Flow Cytometry | Human | 70–250 kDa | Detects multimeric SDC1 forms |
*MW: Molecular weight. Sources: .
IHC Protocol: Heat-mediated antigen retrieval (Tris/EDTA buffer, pH 9.0) is critical for optimal detection in paraffin-embedded tissues .
Flow Cytometry: SDC1 antibodies like ab128936 and ARG66252 exhibit strong signals in fixed/permeabilized cells (e.g., HeLa, Raji) .
SDC1 migrates as multiple bands (35–250 kDa) due to post-translational modifications (e.g., glycosylation) .
Example: ab128936 detects a 100 kDa band in Ramos cells and a 35 kDa band in Raji cells .
Immune Regulation: SDC1 deficiency reduces T cell proliferation and IL-17 production in dendritic cell (DC)–T cell co-cultures .
Neurodegeneration: Syndecans mediate α-synuclein and tau fibril uptake in neuronal cells, implicating SDC1 in prion-like protein spread .
Biomarker Potential: SDC1 is overexpressed in multiple myeloma (as CD138) and breast cancer, making it a target for antibody-based therapies .
Therapeutic Target: Soluble SDC1 modulates CXCL1 activity, influencing neutrophil recruitment in tumors .